Ibrutinib, as a BTK inhibitor, can inhibit the growth of tumor cells and promote apoptosis by regulating the tumor microenvironment, reducing the secretion of chemokines and proinflammatory factors, and downregulating the expression of anti-apoptotic proteins bcl-2 family. Here, BCL2 is linked to neoplasm.